Since his Parkinson’s diagnosis 13 years ago, Alex Flynn has completed a staggering number of adventures – from finishing a 160-mile run in the Bavarian Alps in Germany, to cycling, climbing, kayaking and running his way across 3,256 miles of America. As he works on plans to become the first person with Parkinson’s to climb Everest, find out how he approaches fundraising for the condition – and what motivates him to keep moving
It was shortly after his Parkinson’s diagnosis in 2008 that Alex Flynn, a 36-year-old UK-based lawyer, made the decision to carry through a commitment to take part in the Marathon des Sables. This was no small prospect – the six-day,150-mile race in southern Morocco has been described as ‘the toughest footrace on Earth’.
“I thought long and hard about whether or not I should go ahead and do the race,” he explains. “One thing that struck me was that if I don’t keep moving, I’m going lose it. Parkinson’s is about rigidity, and the more you move the better off you are. I took heed of my own advice and went out and promptly got lost in the Sahara Desert.”
Far from being put off by the experience, Alex decided that, having raised £1,500 for charity Parkinson’s UK by taking part in the ultra-marathon, he wanted to do more. It was a conversation with a friend following the race that set the course for the next 12 years of adventuring.
“I came back licking my wounds and sat having a cup of coffee with my mate Rich. He said, ‘how much more money do you want to raise?’. I said, ‘a million pounds’ and he said, ‘how are you going to do that?’ and I said, ‘well, running a million metres – a pound per metre.’
“He laughed and said, ‘that’s only 620 miles, mate’ so I said, ‘I’ll make it 10 million metres then’.”
“You’ve got to do something big”
This was the start of Alex’s 10MillionMetres challenge, which saw him undertake an astonishing series of adventures to raise money for Parkinson’s research – from venturing from London to Rome in 30 days with a fractured tibia, to completing a 160-mile run in the Bavarian Alps. One particular highlight was an arduous but rewarding journey across America.
“When the plan for America came up, people asked, ‘do you really need to do something that big?’. And I said, yes! Because once you’ve done something like run across a continent, where do you go? You’ve got to do something big. I decided to do four different disciplines, cycling, climbing, kayaking and running, across 3,256 miles.”
After traversing for 35 days across Santa Monica, Las Vegas, Buffalo and Toronto to New York’s Washington Bridge, city restrictions thwarted a planned finish at the Statue of Liberty – “Thankfully, I was very grateful about that because I was knackered”, he says.
Looking back at the experience, Alex adds: “It was incredibly dangerous at times and was a real adventure. It was very, very hard – and set me up for something even harder, which was expedition race Primal Quest in 2018. I did around 220 miles in four days and five hours across bear-infested parts of British Columbia, Canada, and it almost killed me. I had about 20 days to get fit for the race, and I felt every single metre.”
Alex completed his 10MillionMetres challenge in January 2014 – but continues to fundraise, and to date has raised an estimated US $530,000. How does he stay resilient in the face of formidable challenges?
“The injustice of Parkinson’s motivates me,” he says. “Also having the ability to go out and put one’s life in context and come out of it with plans and ideas. When I crossed America, I had a lot of time on my own, and I was inside my head thinking of all the things I needed to sort out. By the end of the trip I was completely zen.
“What inspires me now is there are many people who are far worse off than me or have just been diagnosed. I want to show them that they can still keep going, they can still do what they’d thought previously impossible as a consequence of their condition. Hopefully if I can do it, they can do it.”
Alex Flynn riding across the Mojave Desert, US, as part of the 2012 Trans-America challenge. (Credit: 10MillionMetres)
Climbing mountains in lockdown
The coronavirus lockdown over the last few months has restricted travel and made international adventuring impossible, but Alex hasn’t let the crisis deter him. Instead, he’s taken a creative approach to continuing his adventures.
“I had some races lined up that had been postponed and I thought, well, why don’t I do some stair climbing, or how about a marathon? Why don’t I do a vertical marathon and see how long it takes me? I reckoned it would take me a couple of days, and I was so wrong – because a vertical marathon is 2.3 times the height of Everest. It took me seven and a half days.”
Alex describes this demanding experience as “a war of attrition” against his body and mind. He says: “I lost an extraordinarily large amount of weight and I went through about 35,000 calories in energy. My left calf muscles absolutely killed me, my achilles tendon was painful, swollen and inflamed, and even going down the stairs normally was painful. And then, of course, there’s the monotony of the same thing every single moment of the day for 10 hours a day every day.”
His endeavour has raised £3,622 for Parkinson’s UK – but reflecting on his achievements can feel surreal. “I’m one of these people that gets numb about it,” he says. “I don’t think much about it, and then I look back and think ‘did I really do that? Was that me?’. And that always surprises me.”
“Challenge yourself in whatever way you can”
Alex still has plenty of adventures in mind. Among his goals, he lists finishing the 4 Deserts Grand Slam, and climbing Mount Blanc, Europe, and Mera Peak, Nepal.
But, he suggests, in three or four years’ time, he may look to a different kind of adventure.
“I’m optimistic that I can still keep going but I’m also partly realistic in saying that I need to make alternative plans and do what most people do when they have Parkinson’s. My Everest could be a literal mountain, but for somebody else it might be the sitting room that they have to get across, or doing up their shoelaces.
“You may need to adapt your viewpoint and challenge yourself in whatever way you can. And if that means running marathons instead of ultra-marathons, then I will adapt. Then, if it’s 5ks instead of these marathons, I will adapt, and if it means walking down the road to the shops, I will adapt. I’ll just keep going.”
Alex Flynn (right) took part in the Trans-Europe challenge in 2011. (Credit: John Saunders photography)
Lead image credit: Scott Gilmour
This article was first published 16 July 2020.
Need to know
Alex Flynn is an adventurer, athlete and father of three. An ex-lawyer, he was diagnosed with Parkinson’s in 2008 at the age of 36. Since his diagnosis, he has undertaken a series of challenges to raise money for Parkinson’s charities – and achieved his goal of covering 10 million metres in 2014. Recently, he completed a vertical marathon, using his staircase to climb the equivalent distance of more than two times the height of Mount Everest. He is based in Oxfordshire, UK, where he lives with his partner, Justine. Find out more about Alex here.
How DBS can help improve Parkinson’s mobility issues
Learn about the ACTIVA™ RC Neurostimulator from Medtronic
24 hours ago
Sir Billy Connolly: Parkinson’s disease is “like a strange animal”
Scottish comedian, actor and musician Sir Billy Connolly has recently discussed his experience of Parkinson’s disease while promoting his new autobiography, ‘Windswept & Interesting’. In an appearance on UK talk show, ‘The Graham Norton Show’, the comedian explained that he had lost the ability to write. He said: “It breaks my heart as I used to love writing letters to people.” Speaking to UK newspaper The Guardian, Connolly added that he thinks the condition is “like a strange animal. One that sits beside you and says, ‘How will you get on without this?’ – before it takes away something else.” Despite these adjustments, Connolly told Norton he has “good days and bad days” with the condition. “It’s creeping up on me and it never lets go,” he said. “I walk like a drunk man and have to have help. So, life is different, but it is good.” Lead image credit:…
New insights on immune cell process and Parkinson’s disease
Insoluble clumps of the protein alpha-synuclein, which can cause damage to brain cells, have been previously linked to Parkinson’s. Now, scientists in Germany, France and the US have uncovered new details on how brain cells respond to these clusters. The researchers discovered that the brain’s immune cells may be able to join together to break down the protein clumps. According to a press release, this was previously unknown. They also found that these neighbouring cells share mitochondria – structures that generate energy for chemical reactions – to help one another. In certain mutations associated with Parkinson’s, this process may be impaired. The researchers hope this insight could inform the development of new therapies. “We have opened the door to a field that will certainly engage researchers for many years to come,” said Professor Dr Michael Heneka, director of the Department of Neurodegenerative Diseases and Geriatric Psychiatry at the University Hospital…
Could analysing skin oil help diagnose Parkinson’s disease?
Parkinson’s disease patients tend to have high levels of oil, known as sebum, on their skin’s surface. Now, a study has suggested that analysing this substance may help when diagnosing the condition. The study revealed that sebum contains significant amounts of genetic material, specifically the molecule ribonucleic acid (RNA). Analysis of RNA contained in sebum – that is, skin surface lipids RNA, or SSL-RNA – could offer insights into a person’s health. Researchers in Japan examined SSL-RNA in men and women with and without Parkinson’s. The results suggested that the SSL-RNA profiles of those with Parkinson’s had “different characteristics” than those without. The researchers then tested whether examining these profiles with machine learning could reveal those who had Parkinson’s – and who didn’t. The team’s algorithm indicated a “relatively robust discriminatory ability,” supporting the further use of SSL-RNA as part of a future “non-invasive” method for diagnosis.